Jazz Pharmaceuticals (JAZZ) reported Q4 non-GAAP earnings late Tuesday of $6.60 per diluted share, up from $5.02 a year earlier.

Analysts polled by Capital IQ expected $5.81.

Revenue for the quarter ended Dec. 31 was $1.09 billion, up from $1.01 billion a year earlier.

Analysts surveyed by Capital IQ expected $1.06 billion.

For the full year 2025, the company expects diluted EPS of $22.50 to $24.00 on revenue of $4.15 billion to $4.40 billion. Analysts are looking for $22.03 and $4.32 billion, respectively.

Shares of Jazz Pharmaceuticals were down 2.6% in recent after-hours activity.